Scholarlink

Background <p>&#xa0;Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that significantly impact quality of life. As the disease advances, treatment options expand from oral medications to include device-aided therapies, which differ widely in their mechanisms, invasiveness, and impact on daily life. These therapies have distinct attributes that may align differently with individual patient preferences; therefore, understanding such preferences is crucial for informed, shared clinical decision making. This scoping review synthesizes quantitative evidence on treatment preferences among people with Parkinson’s disease (PwP), highlighting research gaps on key attributes.</p> Methods <p>&#xa0;A systematic search of PubMed and Embase (January 2026) identified studies using quantitative stated-preference methods—discrete choice experiments, best-worst scaling, conjoint analysis, or threshold techniques—with PwP, care partners, or healthcare professionals. Twelve studies met inclusion criteria.</p> Results <p>&#xa0;Treatment efficacy—particularly increased ‘ON time’ (periods without troublesome dyskinesia)—and treatment modality were the strongest drivers of preferences. PwP favored non-invasive treatments, such as oral or sublingual formulations, over surgical options like deep brain stimulation. Convenience factors, including pill burden and device management frequency, also influenced preferences but were generally secondary to efficacy and modality. Safety attributes, such as risk of depression or cognitive decline, were important but often outweighed by perceived benefits in symptom control. No studies assessed care partners’ preferences for modalities such as subcutaneous infusions.</p> Conclusions <p>&#xa0;PwP prioritize treatment efficacy and non-invasive modalities, with convenience and safety considered secondary. Further research should explore preferences for new treatment modalities and include care partners’ perspectives to optimize treatment planning and outcomes in PD care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preferences for Parkinson’s Disease Treatments: A Scoping Literature Review

  • 期刊论文

  • 发表日期：

    2026年7月22日

查看全文
  • Pablo Arija,
  • Marco Boeri,
  • Connie H. Yan,
  • Zachary Baldwin

摘要

Background

 Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that significantly impact quality of life. As the disease advances, treatment options expand from oral medications to include device-aided therapies, which differ widely in their mechanisms, invasiveness, and impact on daily life. These therapies have distinct attributes that may align differently with individual patient preferences; therefore, understanding such preferences is crucial for informed, shared clinical decision making. This scoping review synthesizes quantitative evidence on treatment preferences among people with Parkinson’s disease (PwP), highlighting research gaps on key attributes.

Methods

 A systematic search of PubMed and Embase (January 2026) identified studies using quantitative stated-preference methods—discrete choice experiments, best-worst scaling, conjoint analysis, or threshold techniques—with PwP, care partners, or healthcare professionals. Twelve studies met inclusion criteria.

Results

 Treatment efficacy—particularly increased ‘ON time’ (periods without troublesome dyskinesia)—and treatment modality were the strongest drivers of preferences. PwP favored non-invasive treatments, such as oral or sublingual formulations, over surgical options like deep brain stimulation. Convenience factors, including pill burden and device management frequency, also influenced preferences but were generally secondary to efficacy and modality. Safety attributes, such as risk of depression or cognitive decline, were important but often outweighed by perceived benefits in symptom control. No studies assessed care partners’ preferences for modalities such as subcutaneous infusions.

Conclusions

 PwP prioritize treatment efficacy and non-invasive modalities, with convenience and safety considered secondary. Further research should explore preferences for new treatment modalities and include care partners’ perspectives to optimize treatment planning and outcomes in PD care.